Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2012

01-10-2012 | Original Article

Variables Associated with Stress Ulcer Prophylaxis Misuse: A Retrospective Analysis

Authors: Iyad A. Issa, Ola Soubra, Hania Nakkash, Lama Soubra

Published in: Digestive Diseases and Sciences | Issue 10/2012

Login to get access

Abstract

Background

Stress ulcer prophylaxis (SUP) is commonly used in hospitals. Although its indications are better delineated for intensive care unit (ICU) patients, its use in non-ICU settings is somewhat arbitrary and based on judgment.

Objective

We attempted to assess the extent of SUP overuse in our hospital. We also carefully collected and analyzed several variables to detect associations governing this flawed behavior and its financial burden on the hospital’s budget.

Materials and Methods

We retrospectively analyzed charts of patients admitted to the medical floor of a tertiary referral university hospital over a 1 year period. All adult patients admitted to the medical ward who received at least one dose of SUP were included and reviewed for a multitude of variables in addition to the appropriateness of acid suppression therapy (AST).

Results

We included 320 charts and found that 92% of patients admitted during that period were not eligible for SUP. The total inappropriateness of SUP was noted to be 58% (p = 0.015). Increasing age and male gender were found to be significant variables in AST misuse (p = 0.045 and p = 0.010), much like duration of hospital stay (p = 0.008). Comorbidities was also found to be a defining variable for AST overuse (odds ratio [OR] = 3.27). Patients with two or more minor risk factors were also subjected more to SUP inappropriately (OR = 3.53), in addition to patients of certain specialties (Neurology, Infectious Diseases, etc.). Our calculated financial burden was more than $23,000 per year for the medical floor.

Conclusion

This retrospective study confirmed the growing suspicion that SUP misuse is evident on the medical floors. We also delineated several factors and variables associated with and affecting SUP overuse.
Literature
1.
go back to reference Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64:1396–1400.PubMedCrossRef Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64:1396–1400.PubMedCrossRef
2.
go back to reference Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am. 2009;38:245–265.PubMedCrossRef Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am. 2009;38:245–265.PubMedCrossRef
3.
go back to reference Nasser SC, Nassif JG, Dimassi HI. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol. 2010;16:982–986.PubMedCrossRef Nasser SC, Nassif JG, Dimassi HI. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol. 2010;16:982–986.PubMedCrossRef
4.
go back to reference Quenot J-P, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009;15:139–143.PubMedCrossRef Quenot J-P, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009;15:139–143.PubMedCrossRef
5.
go back to reference ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56:347–379. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56:347–379.
6.
go back to reference Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104:S27–S32.PubMedCrossRef Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104:S27–S32.PubMedCrossRef
7.
go back to reference Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330:377–381.PubMedCrossRef Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330:377–381.PubMedCrossRef
8.
go back to reference Sesler JM. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. ACCN Adv Crit Care. 2007;18:119–128.CrossRef Sesler JM. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. ACCN Adv Crit Care. 2007;18:119–128.CrossRef
9.
go back to reference Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010;25:214–220.PubMedCrossRef Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010;25:214–220.PubMedCrossRef
10.
go back to reference Terzi Coelho CB, Dragosavac D, Coelho Neto JS, Montes CG, Guerrazzi F, Andreollo NA. Ranitidine is unable to maintain gastric pH levels above 4 in septic patients. J Crit Care. 2009;24:627.e7–627.e13.CrossRef Terzi Coelho CB, Dragosavac D, Coelho Neto JS, Montes CG, Guerrazzi F, Andreollo NA. Ranitidine is unable to maintain gastric pH levels above 4 in septic patients. J Crit Care. 2009;24:627.e7–627.e13.CrossRef
11.
go back to reference Judd WR, Davis GA, Winstead PS, Steinke DT, Clifford TM, Macaulary TE. Evaluation of continuation of stress ulcer prophylaxis at hospital discharge. Hosp Pharm. 2009;44:888–893.CrossRef Judd WR, Davis GA, Winstead PS, Steinke DT, Clifford TM, Macaulary TE. Evaluation of continuation of stress ulcer prophylaxis at hospital discharge. Hosp Pharm. 2009;44:888–893.CrossRef
12.
go back to reference Afif W, Alsulaiman R, Martel M, Barkun AN. Predictors of inappropriate utilization of intravenous proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:609–615.PubMedCrossRef Afif W, Alsulaiman R, Martel M, Barkun AN. Predictors of inappropriate utilization of intravenous proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:609–615.PubMedCrossRef
13.
go back to reference Khalili H, Dashti-Khavidaki S, Hossein Talasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16:114–121.PubMed Khalili H, Dashti-Khavidaki S, Hossein Talasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16:114–121.PubMed
14.
go back to reference Slattery E, Theyventhiran R, Cullen G, et al. Intravenous proton pump inhibitor use in hospital practice. Eur J Gastroenterol Hepatol. 2007;19:461–464.PubMedCrossRef Slattery E, Theyventhiran R, Cullen G, et al. Intravenous proton pump inhibitor use in hospital practice. Eur J Gastroenterol Hepatol. 2007;19:461–464.PubMedCrossRef
15.
go back to reference Qadeer MA, Richter JE, Brotman DJ. Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings. J Hosp Med. 2006;1:13–20.PubMedCrossRef Qadeer MA, Richter JE, Brotman DJ. Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings. J Hosp Med. 2006;1:13–20.PubMedCrossRef
16.
go back to reference Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95:3118–3122.PubMed Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95:3118–3122.PubMed
17.
go back to reference Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203–1209.PubMedCrossRef Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203–1209.PubMedCrossRef
18.
go back to reference Lee EY, Brotz C, Greenwald D. Cost and characteristics of intravenous proton pump inhibitor use and misuse in a tertiary care hospital. Am J Gastroenterol. 2003;98:S54. Lee EY, Brotz C, Greenwald D. Cost and characteristics of intravenous proton pump inhibitor use and misuse in a tertiary care hospital. Am J Gastroenterol. 2003;98:S54.
19.
go back to reference Yap KB, Chan KM. The prescribing pattern of hospital doctors. Singapore Med J. 1998;39:496–500.PubMed Yap KB, Chan KM. The prescribing pattern of hospital doctors. Singapore Med J. 1998;39:496–500.PubMed
20.
go back to reference George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother. 2008;6:249–254.PubMedCrossRef George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother. 2008;6:249–254.PubMedCrossRef
21.
go back to reference Carey IM, De Wilde S, Harris T, et al. What factors predict potentially inappropriate primary care prescribing in older people? Analysis of UK primary care patient record database. Drugs Aging. 2008;25:693–706.PubMedCrossRef Carey IM, De Wilde S, Harris T, et al. What factors predict potentially inappropriate primary care prescribing in older people? Analysis of UK primary care patient record database. Drugs Aging. 2008;25:693–706.PubMedCrossRef
22.
go back to reference Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM. 2010;103:327–335.PubMedCrossRef Craig DGN, Thimappa R, Anand V, Sebastian S. Inappropriate utilization of intravenous proton pump inhibitors in hospital practice—a prospective study of the extent of the problem and predictive factors. QJM. 2010;103:327–335.PubMedCrossRef
23.
go back to reference Alsultan MS, Mayet AY, Malhani AA, Alshaikh MK. Pattern of intravenous proton pump inhibitors use in ICU and non-ICU setting: a prospective observational study. Saudi J Gastroenterol. 2010;16:275–279.PubMedCrossRef Alsultan MS, Mayet AY, Malhani AA, Alshaikh MK. Pattern of intravenous proton pump inhibitors use in ICU and non-ICU setting: a prospective observational study. Saudi J Gastroenterol. 2010;16:275–279.PubMedCrossRef
24.
go back to reference Mayet AY. Improper use of antisecretory drugs in a tertiary care teaching hospital: an observational study. Saudi J Gastroenterol. 2007;13:124–128.PubMedCrossRef Mayet AY. Improper use of antisecretory drugs in a tertiary care teaching hospital: an observational study. Saudi J Gastroenterol. 2007;13:124–128.PubMedCrossRef
25.
go back to reference Cook DJ, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991;91:519–527.PubMedCrossRef Cook DJ, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991;91:519–527.PubMedCrossRef
26.
go back to reference Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275:308–314.PubMedCrossRef Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275:308–314.PubMedCrossRef
27.
go back to reference Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002;30:S373–S378.PubMedCrossRef Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002;30:S373–S378.PubMedCrossRef
28.
go back to reference Perwaiz MK, Posner G, Hammoudeh F, et al. Inappropriate use of intravenous PPI for stress ulcer prophylaxis in an inner city community hospital. J Clin Med Res. 2010;2:215–219.PubMed Perwaiz MK, Posner G, Hammoudeh F, et al. Inappropriate use of intravenous PPI for stress ulcer prophylaxis in an inner city community hospital. J Clin Med Res. 2010;2:215–219.PubMed
29.
go back to reference Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–632.PubMedCrossRef Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–632.PubMedCrossRef
30.
go back to reference Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–740.PubMedCrossRef Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735–740.PubMedCrossRef
31.
go back to reference Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother. 2002;36:1929–1937.PubMedCrossRef Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother. 2002;36:1929–1937.PubMedCrossRef
32.
go back to reference Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004;51:757–761.PubMed Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004;51:757–761.PubMed
33.
go back to reference Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3:430–448.PubMedCrossRef Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3:430–448.PubMedCrossRef
34.
go back to reference Penston J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol. 1986;1:192–216.PubMed Penston J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol. 1986;1:192–216.PubMed
35.
go back to reference Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987;317:1376–1382.PubMedCrossRef Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987;317:1376–1382.PubMedCrossRef
36.
go back to reference Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321:1103–1106.PubMedCrossRef Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321:1103–1106.PubMedCrossRef
37.
go back to reference Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol. 2001;13:611–616.PubMedCrossRef Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol. 2001;13:611–616.PubMedCrossRef
38.
go back to reference Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50:366–372.PubMedCrossRef Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50:366–372.PubMedCrossRef
39.
go back to reference Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–2128.PubMedCrossRef Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–2128.PubMedCrossRef
40.
go back to reference Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54:243–245.PubMedCrossRef Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54:243–245.PubMedCrossRef
41.
go back to reference Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ. 2004;171:33–38.PubMedCrossRef Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ. 2004;171:33–38.PubMedCrossRef
42.
go back to reference Louie TJ, Meddings J. Clostridium difficile infection in hospitals: risk factors and responses. CMAJ. 2004;171:45–46.PubMedCrossRef Louie TJ, Meddings J. Clostridium difficile infection in hospitals: risk factors and responses. CMAJ. 2004;171:45–46.PubMedCrossRef
43.
go back to reference Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39:219–226.PubMedCrossRef Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39:219–226.PubMedCrossRef
44.
go back to reference Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–2056.PubMedCrossRef Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–2056.PubMedCrossRef
45.
go back to reference Erstad BL. Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother. 2001;35:730–740.PubMedCrossRef Erstad BL. Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother. 2001;35:730–740.PubMedCrossRef
46.
go back to reference Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101:2200–2205.PubMedCrossRef Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101:2200–2205.PubMedCrossRef
Metadata
Title
Variables Associated with Stress Ulcer Prophylaxis Misuse: A Retrospective Analysis
Authors
Iyad A. Issa
Ola Soubra
Hania Nakkash
Lama Soubra
Publication date
01-10-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2104-9

Other articles of this Issue 10/2012

Digestive Diseases and Sciences 10/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine